Basilea Pharmaceutica AG (BSLN.S)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|53||2016||Chairman of the Board of Directors|
|50||2018||Chief Executive Officer, Member of the Management Committee|
|2013||Member of the Management Committee, Chief Financial Officer|
|2018||Chief Technology Officer|
|2009||Member of the Management Committee, Chief Scientific Officer|
- BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln
- BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan
- BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia
- BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America
- BRIEF-Basilea Pharmaceutica Presents Phase 1 Clinical Data With Anticancer Drug Candidate Bal101553